Zhejiang Garden Biopharmaceutical (300401) Fundamentals 2026 — P/E 26.5x, Revenue Analysis | SniperIQ
Zhejiang Garden Biopharmaceutical (300401) is a CN-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥6.8B, trading at ¥12.47 on the SHZ. This SniperIQ fundamentals page covers Zhejiang Garden Biopharmaceutical's valuation (P/E 26.5x, P/B 2.0x), profitability (net margin 21.8%), revenue (¥1.2B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Zhejiang Garden Biopharmaceutical's market cap?
Zhejiang Garden Biopharmaceutical (300401) has a market capitalization of approximately ¥6.8B, trading at ¥12.47 on the SHZ. Market cap moves with the live share price.
What is Zhejiang Garden Biopharmaceutical's P/E ratio?
Zhejiang Garden Biopharmaceutical's trailing twelve-month P/E ratio is 26.5x, with a price-to-book (P/B) of 2.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Zhejiang Garden Biopharmaceutical?
Zhejiang Garden Biopharmaceutical runs a net profit margin of 21.8%, a gross margin of 53.5%, and an operating margin of 26.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Zhejiang Garden Biopharmaceutical generate?
Zhejiang Garden Biopharmaceutical reported revenue of ¥1.2B for fiscal year 2025, with net income of ¥305M and earnings per share (EPS) of 0.56. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Zhejiang Garden Biopharmaceutical pay a dividend?
Zhejiang Garden Biopharmaceutical offers a trailing dividend yield of about 0.9%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Zhejiang Garden Biopharmaceutical financially healthy?
Zhejiang Garden Biopharmaceutical carries a debt-to-equity ratio of 0.49x and a current ratio of 2.08x, with a market beta of 0.30. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Zhejiang Garden Biopharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Zhejiang Garden Biopharmaceutical (300401) the key facts are: market cap ¥6.8B, P/E 26.5x, revenue ¥1.2B, 52-week range 10.68-23.44. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Zhejiang Garden Biopharmaceutical's full fundamentals live
Get Zhejiang Garden Biopharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.